clinical trial · NCT06268886
Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease
Bristol-Myers Squibb·phase2·active not recruiting·n = 310
Alzheimer Disease, Early OnsetBMS-986446Placebo
brief summary
The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's Disease.
started
Mar 20, 2024
primary completion
Mar 18, 2027
completion
Mar 18, 2027
last updated
Jul 24, 2025
official title
A Randomized, Double-blind, Placebo-controlled, Global Proof-of-concept Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants With Early Alzheimer's Disease (TargetTau-1)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol